Aug 2026· Journal of Medicinal Chemistry· Vol 69, pp. 19822 - 19840· 1 citation· 49 references
Medicine
TL;DR
LD5095 demonstrates potent and selective RIPK1 degradation across cell lines, with rapid kinetics and sustained degradation over 72h post-washout, and exhibited favorable pharmacokinetics, including metabolic stability and an extended half-life.
Abstract
Receptor-interacting protein kinase 1 (RIPK1) is a critical regulator of programmed cell death and is implicated in various pathological conditions, particularly in mediating tumor resistance to immune checkpoint inhibitors (ICBs). In this study, we have pioneered the development of a novel cereblon (CRBN)-recruiting RIPK1 degrader, LD5095 , through systematic optimization of linker and CRBN ligand portion. LD5095 demonstrates potent and selective RIPK1 degradation across cell lines, with rapid kinetics and sustained degradation over 72h post-washout. Functionally, RIPK1 degradation by LD5095 significantly sensitized Jurkat cells to TNFα-induced apoptosis. Furthermore, LD5095 exhibited favorable pharmacokinetics, including metabolic stability and an extended half-life. Strikingly, in vivo, a single dose of LD5095 achieved durable RIPK1 degradation in xenograft tumors over 6 days. These findings underscore the potential of LD5095 as a chemical probe for studying RIPK1 biology and a promising candidate for cancer treatment.
Activating NRAS mutations occur in approximately 20% of melanomas but remain largely undruggable due to the lack of effective targeted therapies. We previously identified casein kinase 1δ (CK1δ) as a critical upstream regulator that stabilizes oncogenic NRAS mutants. However, no selective CK1δ inhibitors have advance...
Chang-Fa Zhang, Ya-Lei Wen, Jian-Qiao Yi et al.· Journal of Medicinal Chemist...· 0 citations
Immune checkpoint inhibitors (ICIs) are first-line therapy for cervical cancer (CC), yet their efficacy is limited to a subset of patients owing to low tumor immunogenicity. Single-cell RNA sequencing revealed that CC patients exhibiting robust immune responses following radiotherapy (RT) showed upregulation of necropt...
Tong Wu, Bin Lv, Han Wang et al.· Bioactive Materials· 0 citations
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related morbidity worldwide, with fibroblast growth factor receptor 1 (FGFR1) playing a pivotal role in its pathogenesis and progression. Although FGFR1-targeted therapies, particularly tyrosine kinase inhibitors (TKIs), have shown clinical efficacy, their...
Zi-Yu Tian, Lu-Wei Fu, Xuan-Xuan Yan et al.· European journal of medicina...· 0 citations
The serine/threonine kinase PAK1 is increasingly recognized as a pivotal regulator of tumor progression and immune evasion in triple-negative breast cancer (TNBC). However, the development of PAK1 inhibitors with both high potency and favorable drug-like properties remains challenging. Herein, we report the design, syn...
Hong-Lei Bao, Yu-Pei Lai, Xi Zhao et al.· European journal of medicina...· 0 citations
This work describes the design, synthesis, and biological evaluation of a series of JNK1-targeting PROTACs that recruit either CRBN or VHL E3 ligases that demonstrates excellent degradation potency and selectivity for JNK1, highlighting its potential as a valuable chemical probe for EMT-associated pathologies.
Shuhua Ren, Ye Zhang, Rui Hao et al.· Bioorganic chemistry (Print)· 0 citations
The design and synthesis of SHP2 PROTACs that recruit the DCAF16 E3 ligase for targeted SHP2 degradation are reported that support the potential of SHP2-targeted protein degradation as an alternative strategy to enzymatic inhibition and provide a promising starting point for the further development of SHP2 degraders.
X. Pang, Yuxin Gan, Qing-Yuan Hu et al.· Bioorganic chemistry (Print)· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
